Voyager Therapeutics (VYGR) Reports Q4 Loss, Misses Revenue Estimates

Group 1 - Voyager Therapeutics reported a quarterly loss of $0.59 per share, which was worse than the Zacks Consensus Estimate of a loss of$ 0.35, and a significant decline from earnings of $1.25 per share a year ago, indicating an earnings surprise of -68.57% [1] - The company posted revenues of$ 6.28 million for the quarter ended December 2024, missing the Zacks Consensus Estimate by 68.81%, and a sharp decline from year-ago revenues of $90.06 million [2] - Voyager Therapeutics shares have declined approximately 26.5% since the beginning of the year, contrasting with the S&P 500's decline of -4.5% [3] Group 2 - The earnings outlook for Voyager Therapeutics is mixed, with the current consensus EPS estimate for the coming quarter at -$ 0.37 on revenues of $18.69 million, and for the current fiscal year at -$ 1.59 on revenues of $88.9 million [7] - The Medical - Biomedical and Genetics industry, to which Voyager Therapeutics belongs, is currently ranked in the top 29% of over 250 Zacks industries, suggesting a favorable industry outlook [8]